Determinants of stigma in a cohort of hellenic patients suffering from multiple sclerosis: a cross-sectional study by unknown
RESEARCH ARTICLE Open Access
Determinants of stigma in a cohort of
hellenic patients suffering from multiple
sclerosis: a cross-sectional study
Maria Anagnostouli1*, Serafeim Katsavos1, Artemios Artemiadis1, Markos Zacharis1, Paraskevi Argyrou1,
Ilia Theotoka2, Fotini Christidi1, Ioannis Zalonis1 and Ioannis Liappas2
Abstract
Background: Patients suffering from several neurologic disorders may bear the “stigma” of their disease, being
disqualified from full social acceptance. Although stigma is considered to be present in Multiple Sclerosis (MS), the
factors that influence its levels are ambiguous. Aim of our study was to examine, for the first time in the literature,
the basic determinants of stigma in a Hellenic MS-patients cohort, as well as how stigma affects their Quality-of-Life
(QoL) profiles.
Methods: Three hundred forty two patients were recruited in this study. Data collected concerned sociodemographic
and disease-related variables, mental illness assessment, Multiple-Sclerosis-QoL-54 (MSQoL-54) and Stigma-Scale-for-
Chronic-Illness-24 (SSCI-24) questionnaires. Potential determinants were evaluated with univariate statistical analyses for
their contribution to total, internalized (inner-self derived) and externalized (society derived) stigma. Important findings
were further evaluated on hierarchical regression models.
Results: Disability levels were found to be the most powerful predictor in all stigma categories, followed by the presence
of mental illness. Working and caregiving status were also ascertained as determinants of internalized stigma. Stigma
levels displayed strong negative correlation with all composites of MSQoL-54.
Conclusions: Stigma is present in the social environment of MS patients and was confirmed as a barrier (according to
the International Classification of Functioning, Disability and Health), with detrimental effects on their QoL levels and
functioning performances. Disability and mental illness were shown as the principal determinants of stigma, while
financial characteristics were not as equally involved. Further validation of these results in other MS populations may
provide safer conclusions, towards more efficacious patient-centered care outcomes.
Keywords: Multiple sclerosis, Stigma, Quality of life, Stigma Scale for Chronic Illness (SSCI) Questionnaire, Socioeconomic
parameters, Hellenic population
Background
Multiple Sclerosis (MS) is the most common demyelinating
disease of the Central Nervous System [1]. MS patients
have to cope with multiple different consequences of their
disorder on their ambulation and general physical health.
Inevitably, their overall perceived Quality of Life (QoL) is
influenced negatively [2–4]. QoL as a concept reflects the
degree in which a person’s hopes and ambitions meet his
everyday experiences [5]. In medical literature, various mea-
sures of Health-Related QoL (HRQoL) are usually applied
in order to determine the influence of a given disease under
investigation on an individual’s perceived well-being, social
interactions and overall life perception [6, 7]. HRQoL
measures are unique in that they provide important,
patient-derived information which is not always in accord-
ance with the impressions of the physicians, like the infor-
mation provided by the Expanded Disability Status Scale
(EDSS) scores, for instance [3, 8–12]. Moreover, therapeutic
success may not always be accompanied by favorable QoL
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outcomes and vice-versa [11, 13]. From this point of view
HRQoL measures may help in actively involving MS
patients in clinical decision-making [14], towards more
efficacious patient-centered care outcomes.
Previous efforts to clarify the basic determining factors
of QoL alterations in a variety of medical conditions led
to the conclusion that the amount of stigma borne by
patients plays a fundamental role. Stigmatized patients
tend to seek isolation, which in turn causes decreased
use of healthcare services, poor health outcomes and
poor QoL [15–17]. Stigma was first defined by Goffman,
in 1963 as “the situation of the individual who is
disqualified from full social acceptance” [18], with an
obvious consequence of social isolation – feelings of
rejection. A recent revision defines stigma as “a social
process, experienced or anticipated, characterized by
exclusion, rejection, blame or devaluation that results
from experience, perception or reasonable anticipation
of an adverse social judgement about a person or group”
[19]. People experiencing stigmatization to their social
environment, like the ones with neurological disability,
tend to acquiesce to society’s devaluation and the
negative stereotypes become an accepted part of their
concept of the disorder. This negative influence finally
acts as a barrier, according to the International Classifi-
cation of Functioning, Disability and Health (ICF) of the
World Health Organization (WHO), lowering their
functioning performances. Rao et al. at [20] developed
the Stigma Scale for Chronic Illness (SSCI) as an instru-
ment of measuring stigma across neurological condi-
tions. They distinguished stigma in felt/perceived stigma
(the awareness of a discriminatory stereotype in the
patient’s social environment), enacted stigma (the actual
experience of a discriminatory behavior), and self-stigma
(internalization and acceptance of the negative stereo-
type, leading to shame and low self-esteem). Patients
experiencing stigma are prone to increased psychological
distress, like anxiety and depression [21] and they
display poor health outcomes [22, 23].
The previously discussed conclusions led inevitably in
several attempts of further clarification of stigma’s implica-
tions in a variety of neurological, among others, conditions.
SSCI scores were found similar in people with chronic mi-
graine and people with epilepsy, but higher than those
measured in people with episodic migraine [24]. Enacted
stigma in epilepsy has been repeatedly correlated negatively
with QoL levels [25, 26]. Functional somatic syndromes,
like chronic fatigue syndrome and fibromyalgia, were
connected with greater levels of perceived stigma in
comparison to a group of autoimmune disorders, with MS
among them [27], which was attributed to the ambiguity in
the diagnosis of the first group of situations. Finally, pa-
tients suffering from Amyotrophic Lateral Sclerosis (ALS)
may be stigmatized more severely than those suffering
from MS or Parkinson’s disease [28]. Nevertheless, social
isolation has been reported among the basic determinants
of HRQoL measures reduction in patients with Parkinson’s
disease, in a previous study which was also conducted in
the Hellenic population [29].
It is obvious that the aforementioned reports examined
stigma in MS along with other neurological conditions, in
a principal perspective of simply comparing the estimated
levels. Little is known though about the basic factors
which determine the stigma that MS patients encounter.
Feeling stigmatized because of MS is beyond doubt, influ-
encing the patients’ social relationships [30] and coercing
them in developing manipulative behavioral strategies in
order to cope [31]. From this point of view, increased
comorbidity of mental illness in MS populations does not
come at all as a surprise [32].
The aim of this cross-sectional study was to investigate
the basic determinants of stigma in a Hellenic MS-patients
cohort, as well as how stigma affects their Quality-of-Life
(QoL) profiles. Besides, our study was performed during
the years of economical crisis in Greece, when patients
were expected to perceive the consequences of their health
problems even more intensely [33, 34].
Methods
This is a cross-sectional study that took place in the
outpatient clinic (OTPC) of the 1st Department of
Neurology, of Medical School, of Athens National and
Kapodistrian University, at Aeginition Hospital, from
November 2011 to June 2014. The study protocol was
approved by the Hospital’s Scientific and Ethics Com-
mittee as it was found consistent with the Declaration of
Helsinki. MS patients who visited our OTPC were diag-
nosed as having clinically definite MS (CDMS) according
to McDonald (2010) criteria [35]. Their origin was from
all over Greece, since our MS Center is one of the biggest
in Athens and generally in Greece. The patients were not
related to each other. During the recruitment period MS
patients visiting the OTPC were asked to fill in the study's
questionnaires, after being fully informed about its
content and the study’s goal. Patients were also asked to
provide their written informed consent before answering
the questionnaires. All participants that were unable to fill
in the questionnaires due to serious problems in vision,
hearing and/or understanding were excluded from the
study. With regard to intelligence and cognition, in par-
ticular, all patients recruited should have a full intelligence
quotient (FIQ of Wechsler Adult Intelligence Scale) above
79 [36], and a Mini-Mental State Examination score above
24 [37]. A medical doctor of the study’s team, along with
an experienced social worker was responsible for helping
and answering queries of the patients. The same medical
doctor along with an experienced neurologist was respon-
sible for gathering data related to MS. After that, each
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patient underwent screening by a trained clinical psych-
ologist and evaluation by an experienced psychiatrist, for
the detection of a potential mental illness. At the end of
the recruitment period an independent researcher (not
knowing the patients or their names) created the elec-
tronic database which served for purposes of statistical
analyses.
Measurements
1. Sociodemographical characteristics included: age,
gender, marital status (married or living with others/
unmarried or living alone), educational level (primary
or secondary/tertiary), working status (working or
student or pensioner/not working), and income
per month (below 500 euros/500 or more euros).
2. Disease related characteristics: EDSS score, duration
of disease in months, type of MS (relapsing-remitting/
progressive), taking MS immunomodulatory drugs
(yes/no), presence of at least one family member with
MS (yes/no), needing a caregiver or not (yes/no)
assessed by the following question: “Is there someone
that you need to help you cope with your daily needs
or care?”.
3. Healthy Lifestyle Score: This is a score reflecting the
degree to which an individual follows a healthy daily
lifestyle. Previous reports on the influence of dietary
habits, exercise and smoking in MS outcomes,
justified the introduction of this measure in our
research [38, 39]. The score is derived by taking into
account smoking, exercise and dietary habits using
the following questions and scoring: 1. “Do you
smoke?” Answers: No or past smoking = 2,
Occasionally = 1, At least 20 cigarettes per day = 0, 2.
“Do you exercise regularly i.e. at least 30 min each
time?” Answers: No = 0, once or twice per week = 1,
at least twice per week = 2, 3. “Please indicate the
frequency that you eat each food category during a
regular week” Answers: for fish/fruits/vegetables/
legumes are scores as No = 0, once per week = 1,
at least once per week = 2, while meat is reversely
scored. Higher scores indicate healthier lifestyle
(min = 0, max = 12).
4. Stigma Scale for Chronic Illness-24 (SSCI-24): This
questionnaire quantifies the impact of stigma in
patients with chronic illnesses [20]. The first thirteen
items refer to the internalized (self ) stigma (SSCI-I)
asking the patient about feelings and thoughts about
his/her condition (i.e. Item 7: “Because of my illness,
I worried that I was a burden to others”). The next
eleven items formulate the externalized (enacted)
stigma subscale (SSCI-E) asking the individual about
instances of actual discrimination related to the
disease (i.e. Item 16: “Because of my illness, people
were unkind to me”). Total score is calculated by
simply adding the previous scores. Higher scores
indicate higher stigma related to the chronic disease.
Internal consistency of the scale in this study was
found high (Cronbach’s alpha 0.921).
5. M.I.N.I. International Neuropsychiatric Interview:
This is a short structured diagnostic interview,
developed jointly by psychiatrists and clinicians in
the United States and Europe, for DSM-IV and
ICD-10 psychiatric disorders [40]. Its Hellenic
version was introduced in 2004 and it has been used
since then in Hellenic populations as a screening
tool for psychiatric disorders [41]. The interview was
undertaken by a trained clinical psychologist. MS
patients were evaluated for the presence or not of
at least one of the following psychiatric disorders:
major depressive episode, major depressive episode
and melancholy, dysthymia, suicidality, (hypo) manic
episode, panic disorder, agoraphobia, social phobia,
obsessive compulsive disorder, post-traumatic stress
disorder, alcohol addiction/abuse, other substance
addiction/abuse, psychosis, anorexia nervosa,
bulimia nervosa, generalized anxiety disorder
and antisocial personality disorder.
6. Multiple Sclerosis Quality of Life-54 (MSQoL-54):
The MSQoL-54 is a structured, self-reported,
multidimensional health-related quality of life
measure [42]. This 54-item instrument generates
12 subscales: physical function, role limitations-
physical, role limitations-emotional, pain, emotional
well-being, energy, health perceptions, social
function, cognitive function, health distress, overall
quality of life, and sexual function. The summary
scores are the physical health composite summary
and the mental health composite summary derived
from a weighted combination of scale scores. Higher
scores indicate better quality of life for each composite.
Statistical analyses
The main characteristics of our sample are presented
with descriptive statistics e.g. means, standard deviations
(SD), minimum and maximum values and frequencies.
Each characteristic was evaluated for its contribution to
stigma (SSCI-T, SSCI-I, SSCI-E) by performing univariate
analyses. For interval measurements we have used
Pearson’s r correlation. For categorical data we performed
Mann–Whitney tests. The reason for choosing these tests
is that although our sample was large, normality tests
(Kolomogorov-Smirnov) and Q-Q plot inspections
revealed lack of normality between groups. Each char-
acteristic showing significant correlation with stigma
was deemed as candidate determinant of stigma in
the following hierarchical regression models. These
models were created using a backward elimination
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method, after checking for models’ accuracy (e.g. influen-
tial statistics) and generalization (e.g. multicolinearity, ho-
moscedasticity, normality and independence of residuals
and linearity between independent variables and stigma).
For each model adjusted R square is presented reflecting
the percentage of variance of stigma explained by the
models’ predictors. Level of significance was set at 0.05.
Statistical analyses were done using SPSS 21.0 software
(SPSS Inc., Chicago, IL, USA).
Results
Table 1 presents the main characteristics of our sample.
Missing data were low, except for income per month
(35.1 %). Our sample consisted of 342 MS patients of
whom the majority were females (67.5 %), with a mean
age of 43.06 years, mostly married or living with someone
(56.4 %) and of primary or secondary education (52 %),
currently not working (79.8 %). The majority of patients
reported that they had a caregiver for their daily care or
needs (57.9 %), while their median EDSS score was 3.0.
The mean duration of disease was 12.25 years and most
patients had the relapsing-remitting type of the disease
(67.6 %). Surprisingly, 30.1 % of the patients were not
receiving any immunomodulatory or other main therapy
for MS. 13.5 % of them reported at least one relative diag-
nosed with MS. The mean healthy lifestyle score was 6.96
(range: 1–12). The M.I.N.I interview and the subsequent
psychiatric evaluation revealed that 36.5 % of patients had
at least one psychiatric disorder. Generalized anxiety
disorder was the most common (30.3 %), followed by
major depressive episode (25.7 %) and dysthymia (23.4 %).
Agoraphobia was present in 3.3 % of cases, while panic
disorder and obsessive-compulsive disorder were present
in 2.3 and 2.2 % of cases respectively. Other disorders (like
alcohol abuse, substance abuse and anorexia nervosa)
were present in a smaller percentage of cases.
Table 2 presents the results of the univariate analyses of
the relationships between the characteristics presented in
Table 1 and stigma total and subscale scores. It is evident
that with increasing age all three stigma scores also in-
crease, reaching statistical significance (SSCI-T p = 0.001,
SSCI-I p = 0.001, SSCI-E p = 0.006). Also, absence of work
(or being a student or a pensioner) was related with higher
total (p = 0.018) and internalized (p = 0.018) stigma. Simi-
larly, an income of below 500 euros per month was signifi-
cantly associated with increases of all three stigma scores
(SSCI-T p = 0.003, SSCI-I p = 0.009, SSCI-E p = 0.013).
However, due to increased missing values no further ana-
lyses was conducted with this characteristic. All stigma
scores were found also significantly increased in patients
needing a caregiver (SSCI-T p = 0.002, SSCI-I p = 0.004,
SSCI-E p = 0.007), having higher EDSS scores (p < 0.0001
for all three stigma scores) or longer duration of MS
(SSCI-T p = 0.001, SSCI-I p = 0.004, SSCI-E p = 0.004),
suffering from progressive MS (p < 0.001 for all three
stigma scores, all progressive forms were unified in a com-
mon category for univariate analyses, because of their
small representation in our total sample, as shown in
Table 1), and suffering from at least one psychiatric
disorder (SSCI-T p < 0.001, SSCI-I p < 0.001, SSCI-E
p = 0.005). Interestingly, having a positive family history
for MS was associated with decreased total (p = 0.041) and
internalized (p = 0.05) stigma scores.
Table 3 presents the results of the hierarchical regres-
sion models for the three stigma scores. Not working, the
presence of at least one mental disorder and increased
EDSS were significantly associated with increased total
stigma scores (p = 0.029, <0.0001 and <0.0001 respect-
ively). Accordingly, the standardized beta value of EDSS
(=0.42) was the most potent predictor for total stigma
score. Collectively these characteristics, along with care-
giver status explained 24.8 % of the overall stigma’s vari-
ance. Regarding internalized stigma, the results were
similar (p = 0.04, <0.0001 and 0.001 respectively for the
three discussed predictors) with the addition of caregiver
status (p = 0.038) showing that MS patients needing a
caregiver reported more internalized stigma. EDSS was
again the strongest predictor (standardized beta of 0.28),
while all the predictors presented in Table 2 explained
22.5 % of the total internalized stigma’s variance. On the
other hand, backward elimination method resulted in only
two statistical significant predictors of externalized
stigma, the presence of mental disorder (p = 0.011)
and EDSS (p < 0.0001), with the latter showing again
the strongest contribution (standardized beta of 0.4).
The two predictors explained 17.6 % of the total
externalized stigma’s variance.
Table 4 presents the correlations between stigma
scores and QoL in MS patients. All three stigma scores
showed strong, statistically significant negative correla-
tions with both physical and mental health composites
of the MSQoL-54 questionnaire (p < 0.0001 for all corre-
lations), indicating that higher stigma was associated
with worse quality of life in MS patients.
Discussion
In this study we tried to investigate the putative predictors
of stigma related to MS, adopting a stepwise approach of
several sociodemographic, lifestyle and disease-related
characteristics. In the first step, we checked for all possible
associations by performing simple univariate analyses. In
this step, we recognized several candidate significant
predictors such as age, working status, income, presence
of mental disorder, need for caregiver, disability status,
duration of disease, type of MS and family history of MS.
During the second step of hierarchical regression model-
ing, disability status and presence of mental disorder
remained as the most potent and significant predictors of
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Table 1 Main characteristics of the study’s sample of Multiple Sclerosis (MS) patients (N = 342)








1. Median 3.0 (Min-Max)
(Min-Max) (0–9.0)
2. Subgroups
0–3.5 (%) 210 (61.4)
4–7 (%) 117 (34.2)
>7 (%) 2 (0.6)
Missing (%) 13 (3.8)
Gender Caregiver Type of MS
Males (%) 111 (32.5) Yes (%) 198 (57.9) Relapsing-Remitting (%) 260 (75.8)
Females (%) 231 (67.5) No (%) 144 (42.1) Primary Progressive (%) 17 (5.0)
Missing (%) 0 (0) Secondary Progressive (%) 54 (15.7)
Missing (%) 12 (3.5)
Marital status Mean healthy lifestyle score ± SD 6.96 ± 2.13 Immunomodulatory drug
Married or living with someone (%) 193 (56.4) (Min-Max) (1–12) Yes (%) 227 (66.4)
Unmarried or living alone (%) 142 (41.5) No (%) 103 (30.1)
Missing (%) 7 (2.1) Missing (%) 12 (3.5)
Education Presence of mental disorder Family history of MS
Primary or Secondary (%) 178 (52.0) Yes (%) 125 (36.5) Yes (%) 46 (13.5)
Tertiary (%) 155 (45.3) No (%) 217 (63.5) No (%) 286 (83.6)
Missing (%) 9 (2.7) Missing (%) 0 (%) Missing (%) 10 (2.9)
Working status Income per month
Working/student/pensioner (%) 60 (17.5) <500 (%) 18 (5.3) SD: standard deviation,
Not Working (%) 273 (79.8) ≥500 (%) 204 (59.6) Min: minimum, Max: maximum,












Table 2 Univariate analyses examining candidate predictors of Stigma in Multiple Sclerosis (MS)
SSCI-T SSCI-I SSCI-E SSCI-T SSCI-I SSCI-E
Pearson’s r with age 0.19 0.19 0.16 Caregiver (Mean values ± SD) (Mean values ± SD) (Mean values ± SD)
Yes 40.67 ± 14.87 24.47 ± 10.24 16.2 ± 6.06
No 35.78 ± 11.89 21.29 ± 8.62 14.49 ± 4.55
p value (Pearson’s) 0.001 0.001 0.006 p value (Mann–Whitney)) 0.002 0.004 0.007
Gender (Mean values ± SD) (Mean values ± SD) (Mean values ± SD) Pearson’s r with Healthy Lifestyle Score 0.07 0.06 0.08
Male 37.07 ± 12.51 22.2 ± 8.43 14.87 ± 5.26
Females 39.56 ± 14.57 23.71 ± 10.31 15.85 ± 5.70
p value (Mann–Whitney) 0.17 0.39 0.09 p value (Pearson’s) 0.192 0.276 0.172
Marital Status (Mean values ± SD) (Mean values ± SD) (Mean values ± SD) Pearson’s r with EDSS 0.44 0.40 0.40
Married or living with someone 37.65 ± 12.79 22.33 ± 8.87 15.32 ± 5.49
Unmarried or living alone 40.27 ± 15.36 24.45 ± 10.76 15.81 ± 5.71
p value (Mann–Whitney) 0.19 0.07 0.32 p value (Pearson’s) <0.0001 <0.0001 <0.0001
Education (Mean values ± SD) (Mean values ± SD) (Mean values ± SD) Pearson’s r with duration of disease 0.18 0.16 0.16
Primary or Secondary 39.54 ± 14.85 23.68 ± 10.18 15.86 ± 6.0
Tertiary 37.93 ± 12.86 22.76 ± 9.25 15.18 ± 5.02
p value (Mann–Whitney) 0.44 0.53 0.41 p value (Pearson’s) 0.001 0.004 0.004
Working Status (Mean values ± SD) (Mean values ± SD) (Mean values ± SD) Type of MS (Mean values ± SD) (Mean values ± SD) (Mean values ± SD)
Working/student/pensioner 38.15 ± 14.19 22.82 ± 9.99 15.33 ± 5.53 RR 35.63 ± 11.44 20.97 ± 7.84 14.66 ± 4.8
Not Working 41.19 ± 12.91 24.88 ± 8.6 16.31 ± 5.73 Progressive 46.48 ± 16.25 28.69 ± 11.21 17.8 ± 6.74
p value (Mann–Whitney) 0.018 0.018 0.108 p value (Mann–Whitney) <0.001 <0.001 <0.001
Income per month (Mean values ± SD) (Mean values ± SD) (Mean values ± SD) DMT Drug (Mean values ± SD) (Mean values ± SD) (Mean values ± SD)
<500 (%) 47.44 ± 14.79 28.44 ± 10.03 19.0 ± 6.68 Yes 38.84 ± 13.67 23.46 ± 9.78 15.38 ± 5.19
≥500 (%) 38.24 ± 13.69 22.85 ± 9.37 15.4 ± 5.66 No 38.95 ± 14.63 22.87 ± 9.33 16.08 ± 6.5
p value (Mann–Whitney) 0.003 0.009 0.013 p value (Mann–Whitney) 0.897 0.648 0.909
Presence of Mental Disorder (Mean values ± SD) (Mean values ± SD) (Mean values ± SD) FH of MS (Mean values ± SD) (Mean values ± SD) (Mean values ± SD)
Yes 42.58 ± 15.62 26.04 ± 10.98 16.54 ± 6.02 Yes 36.7 ± 15.31 21.81 ± 10.75 14.88 ± 5.0
No 36.45 ± 12.34 21.53 ± 8.52 14.92 ± 5.2 No 39.17 ± 13.69 23.47 ± 9.42 15.69 ± 5.7
p value (Mann–Whitney) <0.001 <0.001 0.005 p value (Mann–Whitney) 0.041 0.05 0.31
SSCI-T, -I, -E S stigma scale for chronic illness total, internalized, externalized, SD standard deviation, EDSS expanded disability status scale, FH family history, DMT disease-modifying drug












all three stigma scores (total, internalized and external-
ized), implying a putative strong mediating role in the
relationship of the aforementioned excluded predictors
with stigma. Working status and caregiving also seemed
to be associated with internalized stigma, showing that
unemployment (except for students or pensioners) and
the need for a caregiver were associated with increased
thoughts or beliefs related to MS-stigma.
Our findings concerning disability are somehow
expected and in line with previous research on stigma in
other neurological conditions [28]. Increased disability
renders the disease more obvious to a patient’s social
environment, making him more susceptible to incidents
of discrimination [25, 43]. On the other hand, disability
status also influenced internalized stigma, probably by
facilitating thoughts of worthlessness and culpability for
MS progression. After all, these results verify in part Goff-
man’s ideas about the ‘dramaturgical’ aspects of a disabled
person’s identity management. Within this setting, stigma is
not only a result of the objective impairment, but also a
reflection of an individual’s ‘performance’, masking parts of
its bodily functions in order to prevent social discrediting
[18]. Highly disabled individuals have to cope with a con-
tinuous sense of loss of independence, further exacerbated
by a potential need for a caregiver. Probably this is the rea-
son why caregiver status retains its significance as predictor
of internalized, in contrast to externalized stigma. Equally,
actively working provides the necessary financial resources,
which is obviously a sine-qua-non attribute for an individ-
ual in order to feel independent. Absence of occupation
leads inevitably to low self-esteem, which explains the ob-
served interference with internalized stigma. Surprisingly,
despite the ongoing economical crisis in Greece, which in-
fluenced the patients of our MS sample as well (79.8 % not
working), occupational status had much lower influence
than disability and mental illness in total stigma formation.
Its absence of significance in the regression model of exter-
nal stigma determinants is an interesting fact that maybe
reflects the stable Hellenic familial and social solidarity.
An effort to further analyze correlations of stigma with
mental illness should take into account the reciprocal
nature of connection between these two entities. First of
Table 4 Pearson’s r correlations between stigma scores and the






p value (Pearson’s) <0.0001 <0.0001
SSCI-I −0.67 −0.61
p value (Pearson’s) <0.0001 <0.0001
SSCI-E −0.52 −0.43
p value (Pearson’s) <0.0001 <0.0001
SSCI-T, -I, -E S stigma scale for chronic illness total, internalized, externalized,
MSQOL multiple sclerosis quality of life
P values in bold when statistical significance was reached (p < 0.05)
Table 3 Hierarchical regression models presenting predictors of Stigma in Multiple Sclerosis (MS) patients
B (SE) Standardized beta p value Model summary
SSCI-T
Constant 26.99 (2.17) <0.0001 F (4,304) = 26.33,
Working (Ref.: Not working) −3.92 (1.79) −0.11 0.029 P <0.001
Caregiver (Ref.: No) 2.75 (1.46) 0.1 0.06 Adjusted R square = 24.8 %
Presence of Mental Disorder (Ref: No) 5.87 (1.43) 0.2 <0.0001
EDSS 3.42 (0.41) 0.42 <0.0001
SSCI-I
Constant 16.6 (1.6) <0.0001 F (5,303) = 18.86,
Working (Ref.: Not working) −2.59 (1.25) −0.10 0.04 P <0.001
Caregiver (Ref.: No) 2.13 (1.02) 0.11 0.038 Adjusted R square = 22.5 %
Presence of Mental Disorder (Ref: No) 4.23 (1.0) 0.23 <0.0001
Type of MS (Ref.: RRMS) 2.97 (1.61) 0.14 0.065
EDSS 1.54 (0.43) 0.28 0.001
SSCI-E
Constant 10.77 (0.7) <0.0001 F (2,308) = 34.1,
Presence of Mental Disorder (Ref: No) 1.53 (0.6) 0.13 0.011 P <0.001
EDSS 1.3 (0.17) 0.4 <0.0001 Adjusted R square = 17.6 %
SSCI-T, -I, -E S stigma scale for chronic illness total, internalized, externalized, SE standard error, EDSS expanded disability status scale
P values in bold when statistical significance was reached (p < 0.05)
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all, mental illness in the context of MS further limits oc-
cupational opportunities, degree of acceptance from social
networks and familiar structures [44]. Moreover, patients
with mental illnesses seem to accept, at least in some
extent, the alleged devaluating characteristics of their
disorders, with obvious consequences in self-stigma [45].
On the other hand, stigma itself as a constant traumatizing
experience may facilitate the emergence of psychological
distress, depression in particular [21].
Other observed positive correlations with all stigma
types in the univariate analyses included age, MS
duration and type of disease. The loss of significance
of these factors when they entered the regression
models, could be explained by their relation with
disability status. In other words, higher EDSS scores
in higher age, longer disease duration and progressive
forms are probably responsible for the noted signifi-
cance. Lack of association between educational level
and stigma deserves further discussion, especially if co-
evaluating positive correlation with financial status. Previ-
ous researchers attributed correlation of those two factors
with epileptic stigma to a probable cultural shift, due to
longstanding educational efforts taking hold [24]. Perhaps,
in our study group the role of educational status has given
its place to family history. Indeed, Hellenic society
maintains a tight family-centered structure, in con-
trast with other populations that were previously
studied for stigma in other disorders. As a result,
family quite often plays the role of educator, as well
as the role of social integration promoter. In final
analysis, positivity of family history for MS signifies a
much easier acceptance and adjustment of a new MS
case (theory that can explain our findings).
Previous findings about detrimental effects of
increased stigma on QoL in several disorders were
confirmed in our study, also for MS. This conclusion
was clearly indicated by the significant strong negative
correlations with both physical and mental health
composites of the MSQoL-54 questionnaire. Although
findings involved both types of stigma, the internal-
ized type displayed slightly higher predictor qualities
for both MSQoL-54 composites. In other words, MS
patients had lower QoL scores mainly because of
their shame and fear of discrimination, rather than
actual discrimination itself. Besides, it could be hy-
pothesized that experiencing low QoL and feeling
stigmatized are not completely independent situations,
but rather two interdependent aspects of the same
process.
Despite the previously discussed important findings,
one must consider a possible limitation in our study.
Specifically, we used a convenience sample of MS patients
that visited the OTPC of the Neurological Department of
Athens University Hospital (although, as previously stated,
their origins were for all over Greece and non-related
to each other). One must consider the possibility of
some patients from rural regions, who didn’t have the
financial ability to reach our facilities. This fact could
be responsible for a potential bias, blunting the effects of
financial factors in stigma formation. Stigma experiences
probably differ in relation to several sociodemographic
characteristics, like race/ethnicity, even among the citizens
of the same country, let alone the citizens of different
countries. In other words, our results, although based
on a satisfactory number of MS patients in our sample,
are preliminary and any thoughts of generalization in
other populations should be performed with extreme cau-
tion. Nevertheless, to our knowledge, this is the first study
dedicated to the examination of determining factors of
stigma in MS. Moreover, our data openly indicate, that
stigma is not negligible in MS, having strong negative in-
fluence on QoL measures. Social isolation (as an indirect
marker of stigma) has been previously discussed as a
factor which influences negatively QoL of Hellenic
patients with a neurologic condition [29]. However,
observations made in Parkinson’s disease in the
Hellenic population [29] are not easily transferrable to
MS, because of the substantial differences in natural
history and age groups that are mainly affected in these
two disorders. Moreover, our study was conducted in
a period of time when socioeconomic circumstances
were very different.
Conclusions
Overall, the proven existence of stigma in MS is a
matter with potential serious implications that ought
to be addressed. MS patients may tend towards avoid-
ing medical care, with obvious influence in treatment
outcomes. Possible interventions should include
educational programs for the general public and for
caregivers of MS patients, training programs for clinicians
in orientation of more adequate patient-centered care
services, as well as better organization of supporting and
counseling structures. The detrimental effects of the
two most important MS-stigma determinants, disabil-
ity and mental illness, could be abated by the imple-
mentation of a prompt multi-disciplinary therapeutical
approach (collaboration of neurologists, psychiatrists,
psychologists and rehabilitation workers), even at the
beginning of the disease. The occupational status of
MS patients could be protected more adequately by
improving legislation which currently regulates their
occupational rights. Although, we believe that all the
above proposals are in line with the scientific
community’s emerging questionings, further attention
should be provided in this delicate subject, in order
to achieve the desirable outcomes in favor of MS
patients.
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